InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma
InventisBio (Shanghai) has agreed to out-license the rights of its EGFR-T790M tyrosine kinase inhibitor D-0316 in China, Hong Kong and
Continue readingCoverage of Global Pharma Industry News
InventisBio (Shanghai) has agreed to out-license the rights of its EGFR-T790M tyrosine kinase inhibitor D-0316 in China, Hong Kong and
Continue readingUS biotech company Spectrum Pharmaceuticals said that it has submitted a Biologics License Application (BLA) for ROLONTIS (eflapegrastim) to the
Continue readingTeva Pharmaceutical Industries has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the US, a topical prescription medicine
Continue readingThe US Food and Drug Administration (FDA) has accepted to review the New Drug Application (NDA) for KPI-121 0.25%, an
Continue readingUS clinical stage company Vedanta Biosciences has raised $27 million in a Series C financing round to help it advance
Continue readingIndian pharma company Lupin has out-licensed its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US biopharma
Continue readingNovartis has proposed to acquire French contract development and manufacturing organizations (French CDMO) CellforCure from LFB for an undisclosed price.
Continue readingAmgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 710, a
Continue readingUS pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth
Continue readingAstellas acquisition of Potenza : Japanese pharma company Astellas Pharma has exercised an option to acquire US-based Potenza Therapeutics in
Continue reading